



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – October 7, 2016

PROTON THERAPY WORLD MARKET IS EXPANDING FASTER

MEDraysintell releases the fourth edition of its Proton Therapy World Market Report and Directory, a 290-page document that provides a comprehensive review of the world market dynamics. It analyzes both past evolutions and future trends to the year 2030, and contains a detailed profile of 26 promoters, manufacturers or developers of proton and carbon therapy equipment.

The global particle therapy devices market (mainly proton therapy devices) reached US\$ 750 million in 2015. Market growth has accelerated during the last five years, showing an average annual growth rate of 19% from 2010 to 2015. For the first time, the proton therapy world market is anticipated to reach over US\$ 1 billion in 2018, one year sooner than previously estimated. It is projected to reach between US\$ 3.5 and 6.6 billion by 2030, with 1,200 to 1,800 particle therapy treatment rooms open to patients worldwide.

However, in 2015 only 0.5% of the population that needs access to external radiotherapy was treated with proton therapy. Even with 1,800 treatment rooms in 2030, this will allow only 12% of this population to be able to receive proton therapy treatment.

As the market emerges and becomes a real part of the global radiotherapy world, most proton therapy vendors already have, or are developing a compact PT system. Also, several newcomers have recently started the development of proton therapy equipment and should enter the market in the coming years. In addition to proton therapy, there is also an increasing interest toward carbon therapy with the emergence of several projects in a few countries as well as new and existing firms willing to enter this market segment.

MEDraysintell will display its series of market reports and directories during the EANM – European Association of Nuclear Medicine – congress (Barcelona, Spain, October 16-18, 2016).

More information and table of contents is available at: <http://medraysintell.com/Protontherapy.html>

About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00